Cancer Registration Statistics (1/4)
2 tableaux et 141 postes de l’enquête KOSIS « Cancer Registration Statistics », en chiffres et graphiques annuels.
24개 암종/성별 암발생자수, 상대빈도, 조발생률, 연령표준화발생률
Retour en haut성별 계 · 24개 암종별 모든 암(C00-C96)
- All Cancers (C00-C96) Case
- Lip oral cavity and pharynx (C00-C14) Case
- Esophagus (C15) Case
- Stomach (C16) Case
- Colon and rectum (C18-C20) Case
- Liver (C22) Case
- Gallbladder etc. (C23-C24) Case
- Pancreas (C25) Case
- Larynx (C32) Case
- Lung (C33-C34) Case
- Breast (C50) Case
- Cervix uteri (C53) Case
- Corpus uteri (C54) Case
- Ovary (C56) Case
- Prostate (C61) Case
- Testis (C62) Case
- Kidney (C64) Case
- Bladder (C67) Case
- Brain & CNS (C70-C72) Case
- Thyroid (C73) Case
- Hodgkin disease (C81) Case
- Non-Hodgkin lymphoma (C82-C86 C96) Case
- Multiple myeloma (C90) Case
- Leukemia (C91-C95) Case
- Lip oral cavity and pharynx (C00-C14) Percent
- Esophagus (C15) Percent
- Stomach (C16) Percent
- Colon and rectum (C18-C20) Percent
- Liver (C22) Percent
- Gallbladder etc. (C23-C24) Percent
- Pancreas (C25) Percent
- Larynx (C32) Percent
- Lung (C33-C34) Percent
- Breast (C50) Percent
- Cervix uteri (C53) Percent
- Corpus uteri (C54) Percent
- Ovary (C56) Percent
- Prostate (C61) Percent
- Kidney (C64) Percent
- Bladder (C67) Percent
- Brain & CNS (C70-C72) Percent
- Thyroid (C73) Percent
- Non-Hodgkin lymphoma (C82-C86 C96) Percent
- Multiple myeloma (C90) Percent
- Leukemia (C91-C95) Percent
- All Cancers (C00-C96) Crude Rate
- Lip oral cavity and pharynx (C00-C14) Crude Rate
- Esophagus (C15) Crude Rate
- Stomach (C16) Crude Rate
- Colon and rectum (C18-C20) Crude Rate
- Liver (C22) Crude Rate
- Gallbladder etc. (C23-C24) Crude Rate
- Pancreas (C25) Crude Rate
- Larynx (C32) Crude Rate
- Lung (C33-C34) Crude Rate
- Breast (C50) Crude Rate
- Cervix uteri (C53) Crude Rate
- Corpus uteri (C54) Crude Rate
- Ovary (C56) Crude Rate
- Prostate (C61) Crude Rate
- Testis (C62) Crude Rate
- Kidney (C64) Crude Rate
- Bladder (C67) Crude Rate
- Brain & CNS (C70-C72) Crude Rate
- Thyroid (C73) Crude Rate
- Hodgkin disease (C81) Crude Rate
- Non-Hodgkin lymphoma (C82-C86 C96) Crude Rate
- Multiple myeloma (C90) Crude Rate
- Leukemia (C91-C95) Crude Rate
- All Cancers (C00-C96) Age-Standardized Rate
- Lip oral cavity and pharynx (C00-C14) Age-Standardized Rate
- Esophagus (C15) Age-Standardized Rate
- Stomach (C16) Age-Standardized Rate
- Colon and rectum (C18-C20) Age-Standardized Rate
- Liver (C22) Age-Standardized Rate
- Gallbladder etc. (C23-C24) Age-Standardized Rate
- Pancreas (C25) Age-Standardized Rate
- Larynx (C32) Age-Standardized Rate
- Lung (C33-C34) Age-Standardized Rate
- Breast (C50) Age-Standardized Rate
- Cervix uteri (C53) Age-Standardized Rate
- Corpus uteri (C54) Age-Standardized Rate
- Ovary (C56) Age-Standardized Rate
- Prostate (C61) Age-Standardized Rate
- Testis (C62) Age-Standardized Rate
- Kidney (C64) Age-Standardized Rate
- Bladder (C67) Age-Standardized Rate
- Brain & CNS (C70-C72) Age-Standardized Rate
- Thyroid (C73) Age-Standardized Rate
- Hodgkin disease (C81) Age-Standardized Rate
- Non-Hodgkin lymphoma (C82-C86 C96) Age-Standardized Rate
- Multiple myeloma (C90) Age-Standardized Rate
- Leukemia (C91-C95) Age-Standardized Rate
All Cancers (C00-C96) Case
1999 101,854person→2023 288,613person▲ +183.4%
Lip oral cavity and pharynx (C00-C14) Case
1999 1,741person→2023 4,834person▲ +177.7%
Esophagus (C15) Case
1999 1,861person→2023 3,142person▲ +68.8%
Stomach (C16) Case
1999 20,900person→2023 28,943person▲ +38.5%
Colon and rectum (C18-C20) Case
1999 9,783person→2023 32,610person▲ +233.3%
Liver (C22) Case
1999 13,263person→2023 14,707person▲ +10.9%
Gallbladder etc. (C23-C24) Case
1999 3,047person→2023 7,997person▲ +162.5%
Pancreas (C25) Case
1999 2,614person→2023 9,748person▲ +272.9%
Larynx (C32) Case
1999 1,101person→2023 1,254person▲ +13.9%
Lung (C33-C34) Case
1999 13,224person→2023 32,953person▲ +149.2%
Breast (C50) Case
1999 5,888person→2023 29,871person▲ +407.3%
Cervix uteri (C53) Case
1999 4,486person→2023 3,144person▼ −29.9%
Corpus uteri (C54) Case
1999 728person→2023 4,037person▲ +454.5%
Ovary (C56) Case
1999 1,354person→2023 3,299person▲ +143.6%
Prostate (C61) Case
1999 1,454person→2023 22,640person▲ +1457.1%
Testis (C62) Case
1999 129person→2023 315person▲ +144.2%
Kidney (C64) Case
1999 1,416person→2023 7,367person▲ +420.3%
Bladder (C67) Case
1999 2,195person→2023 5,545person▲ +152.6%
Brain & CNS (C70-C72) Case
1999 1,359person→2023 2,080person▲ +53.1%
Thyroid (C73) Case
1999 3,407person→2023 35,440person▲ +940.2%
Hodgkin disease (C81) Case
1999 122person→2023 356person▲ +191.8%
Non-Hodgkin lymphoma (C82-C86 C96) Case
1999 2,064person→2023 6,109person▲ +196.0%
Multiple myeloma (C90) Case
1999 468person→2023 2,099person▲ +348.5%
Leukemia (C91-C95) Case
1999 2,168person→2023 4,218person▲ +94.6%
Lip oral cavity and pharynx (C00-C14) Percent
1999 1.7%→2023 1.7%▲ +0.0%
Esophagus (C15) Percent
1999 1.8%→2023 1.1%▼ −38.9%
Stomach (C16) Percent
1999 20.5%→2023 10%▼ −51.2%
Colon and rectum (C18-C20) Percent
1999 9.6%→2023 11.3%▲ +17.7%
Liver (C22) Percent
1999 13%→2023 5.1%▼ −60.8%
Gallbladder etc. (C23-C24) Percent
1999 3%→2023 2.8%▼ −6.7%
Pancreas (C25) Percent
1999 2.6%→2023 3.4%▲ +30.8%
Larynx (C32) Percent
1999 1.1%→2023 0.4%▼ −63.6%
Lung (C33-C34) Percent
1999 13%→2023 11.4%▼ −12.3%
Breast (C50) Percent
1999 5.8%→2023 10.3%▲ +77.6%
Cervix uteri (C53) Percent
1999 4.4%→2023 1.1%▼ −75.0%
Corpus uteri (C54) Percent
1999 0.7%→2023 1.4%▲ +100.0%
Ovary (C56) Percent
1999 1.3%→2023 1.1%▼ −15.4%
Prostate (C61) Percent
1999 1.4%→2023 7.8%▲ +457.1%
Kidney (C64) Percent
1999 1.4%→2023 2.6%▲ +85.7%
Bladder (C67) Percent
1999 2.2%→2023 1.9%▼ −13.6%
Brain & CNS (C70-C72) Percent
1999 1.3%→2023 0.7%▼ −46.2%
Thyroid (C73) Percent
1999 3.3%→2023 12.3%▲ +272.7%
Non-Hodgkin lymphoma (C82-C86 C96) Percent
1999 2%→2023 2.1%▲ +5.0%
Multiple myeloma (C90) Percent
1999 0.5%→2023 0.7%▲ +40.0%
Leukemia (C91-C95) Percent
1999 2.1%→2023 1.5%▼ −28.6%
All Cancers (C00-C96) Crude Rate
1999 216rate per 100000→2023 564rate per 100000▲ +161.2%
Lip oral cavity and pharynx (C00-C14) Crude Rate
1999 3.7rate per 100000→2023 9.5rate per 100000▲ +156.8%
Esophagus (C15) Crude Rate
1999 3.9rate per 100000→2023 6.1rate per 100000▲ +56.4%
Stomach (C16) Crude Rate
1999 44.3rate per 100000→2023 56.6rate per 100000▲ +27.8%
Colon and rectum (C18-C20) Crude Rate
1999 20.7rate per 100000→2023 63.8rate per 100000▲ +208.2%
Liver (C22) Crude Rate
1999 28.1rate per 100000→2023 28.8rate per 100000▲ +2.5%
Gallbladder etc. (C23-C24) Crude Rate
1999 6.5rate per 100000→2023 15.6rate per 100000▲ +140.0%
Pancreas (C25) Crude Rate
1999 5.5rate per 100000→2023 19.1rate per 100000▲ +247.3%
Larynx (C32) Crude Rate
1999 2.3rate per 100000→2023 2.5rate per 100000▲ +8.7%
Lung (C33-C34) Crude Rate
1999 28rate per 100000→2023 64.4rate per 100000▲ +130.0%
Breast (C50) Crude Rate
1999 12.5rate per 100000→2023 58.4rate per 100000▲ +367.2%
Cervix uteri (C53) Crude Rate
1999 9.5rate per 100000→2023 6.1rate per 100000▼ −35.8%
Corpus uteri (C54) Crude Rate
1999 1.5rate per 100000→2023 7.9rate per 100000▲ +426.7%
Ovary (C56) Crude Rate
1999 2.9rate per 100000→2023 6.5rate per 100000▲ +124.1%
Prostate (C61) Crude Rate
1999 3.1rate per 100000→2023 44.3rate per 100000▲ +1329.0%
Testis (C62) Crude Rate
1999 0.3rate per 100000→2023 0.6rate per 100000▲ +100.0%
Kidney (C64) Crude Rate
1999 3rate per 100000→2023 14.4rate per 100000▲ +380.0%
Bladder (C67) Crude Rate
1999 4.7rate per 100000→2023 10.8rate per 100000▲ +129.8%
Brain & CNS (C70-C72) Crude Rate
1999 2.9rate per 100000→2023 4.1rate per 100000▲ +41.4%
Thyroid (C73) Crude Rate
1999 7.2rate per 100000→2023 69.3rate per 100000▲ +862.5%
Hodgkin disease (C81) Crude Rate
1999 0.3rate per 100000→2023 0.7rate per 100000▲ +133.3%
Non-Hodgkin lymphoma (C82-C86 C96) Crude Rate
1999 4.4rate per 100000→2023 11.9rate per 100000▲ +170.5%
Multiple myeloma (C90) Crude Rate
1999 1rate per 100000→2023 4.1rate per 100000▲ +310.0%
Leukemia (C91-C95) Crude Rate
1999 4.6rate per 100000→2023 8.2rate per 100000▲ +78.3%
All Cancers (C00-C96) Age-Standardized Rate
1999 403rate per 100000→2023 523rate per 100000▲ +29.8%
Lip oral cavity and pharynx (C00-C14) Age-Standardized Rate
1999 6.6rate per 100000→2023 8.8rate per 100000▲ +33.3%
Esophagus (C15) Age-Standardized Rate
1999 8.2rate per 100000→2023 5.5rate per 100000▼ −32.9%
Stomach (C16) Age-Standardized Rate
1999 86rate per 100000→2023 51.4rate per 100000▼ −40.2%
Colon and rectum (C18-C20) Age-Standardized Rate
1999 40.8rate per 100000→2023 58.7rate per 100000▲ +43.9%
Liver (C22) Age-Standardized Rate
1999 52.4rate per 100000→2023 26.1rate per 100000▼ −50.2%
Gallbladder etc. (C23-C24) Age-Standardized Rate
1999 14rate per 100000→2023 13.8rate per 100000▼ −1.4%
Pancreas (C25) Age-Standardized Rate
1999 11.7rate per 100000→2023 17.1rate per 100000▲ +46.2%
Larynx (C32) Age-Standardized Rate
1999 4.8rate per 100000→2023 2.2rate per 100000▼ −54.2%
Lung (C33-C34) Age-Standardized Rate
1999 59.8rate per 100000→2023 57.5rate per 100000▼ −3.8%
Breast (C50) Age-Standardized Rate
1999 17.2rate per 100000→2023 56.8rate per 100000▲ +230.2%
Cervix uteri (C53) Age-Standardized Rate
1999 14.2rate per 100000→2023 5.9rate per 100000▼ −58.5%
Corpus uteri (C54) Age-Standardized Rate
1999 2.4rate per 100000→2023 7.6rate per 100000▲ +216.7%
Ovary (C56) Age-Standardized Rate
1999 4.5rate per 100000→2023 6.2rate per 100000▲ +37.8%
Prostate (C61) Age-Standardized Rate
1999 7.4rate per 100000→2023 39.2rate per 100000▲ +429.7%
Testis (C62) Age-Standardized Rate
1999 0.2rate per 100000→2023 0.6rate per 100000▲ +200.0%
Kidney (C64) Age-Standardized Rate
1999 5.3rate per 100000→2023 13.5rate per 100000▲ +154.7%
Bladder (C67) Age-Standardized Rate
1999 9.8rate per 100000→2023 9.6rate per 100000▼ −2.0%
Brain & CNS (C70-C72) Age-Standardized Rate
1999 4.1rate per 100000→2023 3.9rate per 100000▼ −4.9%
Thyroid (C73) Age-Standardized Rate
1999 9.8rate per 100000→2023 68.9rate per 100000▲ +603.1%
Hodgkin disease (C81) Age-Standardized Rate
1999 0.3rate per 100000→2023 0.7rate per 100000▲ +133.3%
Non-Hodgkin lymphoma (C82-C86 C96) Age-Standardized Rate
1999 7.1rate per 100000→2023 11.1rate per 100000▲ +56.3%
Multiple myeloma (C90) Age-Standardized Rate
1999 1.9rate per 100000→2023 3.7rate per 100000▲ +94.7%
Leukemia (C91-C95) Age-Standardized Rate
1999 6.1rate per 100000→2023 7.8rate per 100000▲ +27.9%
24개 암종/성/연령(5세)별 암발생자수, 발생률
Retour en haut24개 암종별 모든 암(C00-C96) · 성별 계 · 연령별 계
- All Cancers (C00-C96) Case
- Lip oral cavity and pharynx (C00-C14) Case
- Esophagus (C15) Case
- Stomach (C16) Case
- Colon and rectum (C18-C20) Case
- Liver (C22) Case
- Gallbladder etc. (C23-C24) Case
- Pancreas (C25) Case
- Larynx (C32) Case
- Lung (C33-C34) Case
- Breast (C50) Case
- Cervix uteri (C53) Case
- Corpus uteri (C54) Case
- Ovary (C56) Case
- Prostate (C61) Case
- Testis (C62) Case
- Kidney (C64) Case
- Bladder (C67) Case
- Brain & CNS (C70-C72) Case
- Thyroid (C73) Case
- Hodgkin disease (C81) Case
- Non-Hodgkin lymphoma (C82-C86 C96) Case
- Multiple myeloma (C90) Case
- Leukemia (C91-C95) Case
- All Cancers (C00-C96) Age-Specific Rate
- Lip oral cavity and pharynx (C00-C14) Age-Specific Rate
- Esophagus (C15) Age-Specific Rate
- Stomach (C16) Age-Specific Rate
- Colon and rectum (C18-C20) Age-Specific Rate
- Liver (C22) Age-Specific Rate
- Gallbladder etc. (C23-C24) Age-Specific Rate
- Pancreas (C25) Age-Specific Rate
- Larynx (C32) Age-Specific Rate
- Lung (C33-C34) Age-Specific Rate
- Breast (C50) Age-Specific Rate
- Cervix uteri (C53) Age-Specific Rate
- Corpus uteri (C54) Age-Specific Rate
- Ovary (C56) Age-Specific Rate
- Prostate (C61) Age-Specific Rate
- Testis (C62) Age-Specific Rate
- Kidney (C64) Age-Specific Rate
- Bladder (C67) Age-Specific Rate
- Brain & CNS (C70-C72) Age-Specific Rate
- Thyroid (C73) Age-Specific Rate
- Hodgkin disease (C81) Age-Specific Rate
- Non-Hodgkin lymphoma (C82-C86 C96) Age-Specific Rate
- Multiple myeloma (C90) Age-Specific Rate
- Leukemia (C91-C95) Age-Specific Rate
All Cancers (C00-C96) Case
1999 101,854person→2023 288,613person▲ +183.4%
Lip oral cavity and pharynx (C00-C14) Case
1999 1,741person→2023 4,834person▲ +177.7%
Esophagus (C15) Case
1999 1,861person→2023 3,142person▲ +68.8%
Stomach (C16) Case
1999 20,900person→2023 28,943person▲ +38.5%
Colon and rectum (C18-C20) Case
1999 9,783person→2023 32,610person▲ +233.3%
Liver (C22) Case
1999 13,263person→2023 14,707person▲ +10.9%
Gallbladder etc. (C23-C24) Case
1999 3,047person→2023 7,997person▲ +162.5%
Pancreas (C25) Case
1999 2,614person→2023 9,748person▲ +272.9%
Larynx (C32) Case
1999 1,101person→2023 1,254person▲ +13.9%
Lung (C33-C34) Case
1999 13,224person→2023 32,953person▲ +149.2%
Breast (C50) Case
1999 5,888person→2023 29,871person▲ +407.3%
Cervix uteri (C53) Case
1999 4,486person→2023 3,144person▼ −29.9%
Corpus uteri (C54) Case
1999 728person→2023 4,037person▲ +454.5%
Ovary (C56) Case
1999 1,354person→2023 3,299person▲ +143.6%
Prostate (C61) Case
1999 1,454person→2023 22,640person▲ +1457.1%
Testis (C62) Case
1999 129person→2023 315person▲ +144.2%
Kidney (C64) Case
1999 1,416person→2023 7,367person▲ +420.3%
Bladder (C67) Case
1999 2,195person→2023 5,545person▲ +152.6%
Brain & CNS (C70-C72) Case
1999 1,359person→2023 2,080person▲ +53.1%
Thyroid (C73) Case
1999 3,407person→2023 35,440person▲ +940.2%
Hodgkin disease (C81) Case
1999 122person→2023 356person▲ +191.8%
Non-Hodgkin lymphoma (C82-C86 C96) Case
1999 2,064person→2023 6,109person▲ +196.0%
Multiple myeloma (C90) Case
1999 468person→2023 2,099person▲ +348.5%
Leukemia (C91-C95) Case
1999 2,168person→2023 4,218person▲ +94.6%
All Cancers (C00-C96) Age-Specific Rate
1999 216rate per 100000→2023 564rate per 100000▲ +161.2%
Lip oral cavity and pharynx (C00-C14) Age-Specific Rate
1999 3.7rate per 100000→2023 9.5rate per 100000▲ +156.8%
Esophagus (C15) Age-Specific Rate
1999 3.9rate per 100000→2023 6.1rate per 100000▲ +56.4%
Stomach (C16) Age-Specific Rate
1999 44.3rate per 100000→2023 56.6rate per 100000▲ +27.8%
Colon and rectum (C18-C20) Age-Specific Rate
1999 20.7rate per 100000→2023 63.8rate per 100000▲ +208.2%
Liver (C22) Age-Specific Rate
1999 28.1rate per 100000→2023 28.8rate per 100000▲ +2.5%
Gallbladder etc. (C23-C24) Age-Specific Rate
1999 6.5rate per 100000→2023 15.6rate per 100000▲ +140.0%
Pancreas (C25) Age-Specific Rate
1999 5.5rate per 100000→2023 19.1rate per 100000▲ +247.3%
Larynx (C32) Age-Specific Rate
1999 2.3rate per 100000→2023 2.5rate per 100000▲ +8.7%
Lung (C33-C34) Age-Specific Rate
1999 28rate per 100000→2023 64.4rate per 100000▲ +130.0%
Breast (C50) Age-Specific Rate
1999 12.5rate per 100000→2023 58.4rate per 100000▲ +367.2%
Cervix uteri (C53) Age-Specific Rate
1999 9.5rate per 100000→2023 6.1rate per 100000▼ −35.8%
Corpus uteri (C54) Age-Specific Rate
1999 1.5rate per 100000→2023 7.9rate per 100000▲ +426.7%
Ovary (C56) Age-Specific Rate
1999 2.9rate per 100000→2023 6.5rate per 100000▲ +124.1%
Prostate (C61) Age-Specific Rate
1999 3.1rate per 100000→2023 44.3rate per 100000▲ +1329.0%
Testis (C62) Age-Specific Rate
1999 0.3rate per 100000→2023 0.6rate per 100000▲ +100.0%
Kidney (C64) Age-Specific Rate
1999 3rate per 100000→2023 14.4rate per 100000▲ +380.0%
Bladder (C67) Age-Specific Rate
1999 4.7rate per 100000→2023 10.8rate per 100000▲ +129.8%
Brain & CNS (C70-C72) Age-Specific Rate
1999 2.9rate per 100000→2023 4.1rate per 100000▲ +41.4%
Thyroid (C73) Age-Specific Rate
1999 7.2rate per 100000→2023 69.3rate per 100000▲ +862.5%
Hodgkin disease (C81) Age-Specific Rate
1999 0.3rate per 100000→2023 0.7rate per 100000▲ +133.3%
Non-Hodgkin lymphoma (C82-C86 C96) Age-Specific Rate
1999 4.4rate per 100000→2023 11.9rate per 100000▲ +170.5%
Multiple myeloma (C90) Age-Specific Rate
1999 1rate per 100000→2023 4.1rate per 100000▲ +310.0%
Leukemia (C91-C95) Age-Specific Rate
1999 4.6rate per 100000→2023 8.2rate per 100000▲ +78.3%
Ce qu’est cette statistique
Cancer Registration Statistics· 의료기관(암환자 등록) → 중앙암등록본부(접수) → 중앙·지역암등록본부(보고 누락자에 대한 의무기록조사, 자료 정제 및 분석) → 중앙암등록본부(취합) → 보건복지부
- Termes clés
- Pourquoi elle est produite
- 암등록통계자료를 수집, 질관리, 분석하여 국가암관리 정책 및 암연구에 중요한 근거 자료가 되는 국가등록통계(암발생, 암생존, 암유병)자료를 체계적으로 제공하기 위함
상대생존율 : 관심질병을 가진 환자의 관찰생존율을 동일한 성별, 연령군을 가지는 일반인구의 기대 생존율로 나누어 구한 값으로 암 이외의 원인으로 사망했을 경우의 효과를 보정해준 생존율을 의미한다.5년 암유병자수 : 5년 암유병자수는 기준년도의 다음해 1월 1일을 기준으로 이전 5년 동안 암을 진단받은 암환자 중 생존해 있는 암환자 수로 정의된다. 즉, 2018년 5년 유병자는 2014년 1월 1일부터 2018년 12월 31일까지 암을 진단받은 사람 중에서 2019년 1월 1일 기준 생존한 사람의 숫자를 의미한다. 다중원발암이 발생한 사람의 경우 각각을 유병자수에 포함… Lire la suite
상대생존율 : 관심질병을 가진 환자의 관찰생존율을 동일한 성별, 연령군을 가지는 일반인구의 기대 생존율로 나누어 구한 값으로 암 이외의 원인으로 사망했을 경우의 효과를 보정해준 생존율을 의미한다.5년 암유병자수 : 5년 암유병자수는 기준년도의 다음해 1월 1일을 기준으로 이전 5년 동안 암을 진단받은 암환자 중 생존해 있는 암환자 수로 정의된다. 즉, 2018년 5년 유병자는 2014년 1월 1일부터 2018년 12월 31일까지 암을 진단받은 사람 중에서 2019년 1월 1일 기준 생존한 사람의 숫자를 의미한다. 다중원발암이 발생한 사람의 경우 각각을 유병자수에 포함하였다.연령표준화발생률 : 연령표준화발생률은 각 연령군에 해당하는 표준인구의 비율을 가중치로 주어 산출한 가중평균발생률이다. 조발생률은 해당 인구집단에서의 암발생 정도를 절대적으로 평가할 때 주로 사용하며, 지역간 혹은 시기에 따른 암발생률을 비교하기 위해서는 연령구조 차이를 보정한 연령표준화발생률을 사용한다. 표준인구는 우리나라 2000년 주민등록연앙인구를 사용하였다.조발생률 : 조발생률은 해당 관찰기간 동안 특정 인구집단에서 새로이 발생한 암환자수로 정의한다. 일반적으로 인구 100,000명당 발생하는 암환자수로, 소아암의 경우는 1,000,000명당 발생하는 암환자수로 나타낸다. 산출식은 아래와 같다.발생률 = (새롭게 발생한 암환자수/연앙인구 )× 100,000(또는 1,000,000)일 환자에서 발생한 다중원발암(multiple primary cancers)은 중복으로 계산에 포함된다.
🔴 Cette explication a été rédigée par l’organisme qui produit la statistique. DATA CLOCK KOREA ne l’a ni interprétée ni résumée. L’original est en coréen ; nous ne le traduisons pas, car le traduire en ferait autre chose que les mots de l’organisme.
Source des données
- Organisme
- 보건복지부
- Tableau
- 24개 암종/성별 암발생자수, 상대빈도, 조발생률, 연령표준화발생률
- Fournisseur
- KOSIS 국가통계포털
- Période
- 1999 ~ 2023
- Date d’extraction
- 2026-08-29
- Traitement
- KOSIS OpenAPI 로 연간 전국값을 받아 그대로 사용. 가공 없음.
Autres enquêtes de cette catégorie
- Causes of Death Statistics9 tableaux · 199 postes
- Life Tables1 tableaux · 129 postes
- Student Health Examination Statistics3 tableaux · 70 postes
- National Fitness Measurement Statistics11 tableaux · 187 postes
- Medical Service Utilization Status9 tableaux · 184 postes
- Healthcare Quality Statistics24 tableaux · 72 postes